Floatz logo

FILGRASTIM

Plasma Cell Leukemia

National Cancer Institute (NCI)protein_peptidePhase 3Active
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
73/ 100

Competitive context

38 Active assets in the Plasma Cell Leukemia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2BB
Fludarabine
Masonic Cancer Center, University of Minnesota
Phase 2BB
cc-5013
National Cancer Institute (NCI)
Phase 3B
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 3B
Evomela
National Cancer Institute (NCI)
Phase 2B

View all 50 →

Same molecule, other indications

FILGRASTIM is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
79 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →